SCHEMBL2481707

SCHEMBL2481707

Brc1cccc(-c2nn3c(c2-c2ccncc2)SCCCC3)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
MAPK14 Q16539 5/20 0.36
MPO P05164 2/20 0.35
HPGD P15428 3/20 0.34
MAPK11 Q15759 3/20 0.33
GCGR P47871 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPK13 O15264 1/20 0.33
MAPK12 P53778 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CDC7 O00311 1/20 0.32
PGR P06401 1/20 0.31
TGFBR1 P36897 1/20 0.31
MAPT P10636 1/20 0.31
HK1 P19367 1/20 0.31
HKDC1 Q2TB90 1/20 0.31
CHRNB4 P30926 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2480248 0.97 MPO (0.39) RAB9ANPC1MAPK14MPOHPGD
SCHEMBL2481441 0.92 RAB9A (0.39) RAB9ANPC1MAPK14MPOHPGD
SCHEMBL2478416 0.83 FYN (0.40) MAPK14MPOMAPK11MAPK13MAPK12
SCHEMBL2477041 0.83 MPO (0.39) MAPK14MPOTGFBR1
SCHEMBL3465911 0.78 FYN (0.45) MAPK14MPOCDC7TGFBR1
SCHEMBL2476673 0.78 BCHE (0.44) RAB9ANPC1ALDH1A1LMNASMN1; SMN2
SCHEMBL2479421 0.78 FYN (0.41) MAPK14MPOMAPK11MAPK13MAPK12
SCHEMBL2478554 0.78 CYP17A1 (0.37) MAPK14MPOHPGDMAPK11ALDH1A1
SCHEMBL2481187 0.75 GRM5 (0.39) MAPK14CDC7TGFBR1
SCHEMBL2477335 0.75 BRAF (0.47) RAB9ANPC1MAPK14MAPK11GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US disclosed
EP-2373664-B1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP disclosed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US disclosed
EP-2373664-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP disclosed
WO-2010070060-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K19, MAP4K3, MAP3K15 RAB9A 1548/4885NPC1 3581/4885MAPK14 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.